FORM PTO-1390 (Modified) (REV 11-2000)

U.S. DE

ENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ORNEY'S DOCKET NUMBER

025098/0603

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

u.s. APPLICATION NO. (If known, see 37 CFR 1.5)
09/800703054

PCT/US99/20489		10 S ptemb r 1999	11 September 1998
TITLE OF INVENTION			
INHIBITION OF ONCOGENE TRANSCRIPTION BY SYNTHETIC POLYAMIDES			
APPLICANT(S) FOR DO/EO/US Peter B. DERVAN			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
\boxtimes	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.		
	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.		
	This express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21 indicated below.		
	The US has been elected by the expiration of 19 months from the priority date (Article 31).		
\boxtimes	A copy of the International Application as filed (35 U.S.C. 371(c)(2))		
	 is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US) 		
	An English translation of the International Application into English (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154 (d)(4).		
	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))		
	are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have been made and filed in the United States Receiving Office.		
	An English translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).		
Ī	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).		
	An English translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
s 11 to 20	below concern other docume	nt(s) or information included:	
	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.		
	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
	A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.		
	A substitute specification.		
	A change of power of attorney and/or address letter.		
	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 – 1.825.		
	A second copy of the published international application under 35 U.S.C. 154(d)(4).		
	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). Other items of information:		
	PCT/US9 LE OF IN' IBITION (Peter B. I IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	PCT/US99/20489 LE OF INVENTION IBITION OF ONCOGENE TRANSCRIP Peter B. DERVAN Idicant herewith submits to the United State This is a FIRST submission of the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (6), (9) and (21 indicated by the sexpress request to begin (5), (6), (6), (6), (6), (6), (6), (6), (6	PCT/US99/20489 10 S ptemb r 1999 IE OF INVENTION IBITION OF ONCOGENE TRANSCRIPTION BY SYNTHETIC POLYAMID PLICANT(S) FOR DO/EO/US Peter B. DERVAN Illicant herewith submits to the United States Designated/Elected Office (DO/ In his is a FIRST submission of items concerning a filing under 35 lims as SECOND or SUBSEQUENT submission of items concerning a filing under 35 lims express request to begin national examination procedures (3 (5), (6), (9) and (21 indicated below. The US has been elected by the expiration of 19 months from the A copy of the International Application as filed (35 U.S.C. 371(c)(2) is transmitted herewith (required only if not transmitted by the has been transmitted by the International Bureau. Is not required, as the application was filed in the United States has been previously submitted under 35 U.S.C. 154 (d)(4). Amendments to the claims of the International Application under File are transmitted herewith (required only if not transmitted by have been transmitted by the International Bureau. In have been made; however, the time limit for making sure have been made and filed in the United States Receiving Company in the Amendments to the claims of the amendments to the claims under PC Amendment and the company in the United States Receiving Company in the

d T D APR 200 NTERNATIONAL APPLICATION NO. ILS APPLICATION TTORNEY'S DOCKET NUMBER 025098/0603 PCT/US99/20489 Unknown PTO USE ONLY 21.

☐ The following fees are submitted: CALCULATION Basic National Fee (37 CFR 1.492(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO......\$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$860.00 International preliminary examination fee paid (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2) paid to USPTO...... International preliminary examination fee paid (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)...... \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO And all claims satisfied provisions of PCT Article 33 (1)-(4)\$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$860.00 Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)) Claims Number Filed Included in Basic Extra Rate Claims Fee Total Claims 25 20 \$18.00 \$ 90.00 3 0 \$80.00 \$ 0.00 Independent = Claims \$270.00 Multiple dependent claim(s) (if applicable) \$ 0.00 TOTAL OF ABOVE CALCULATIONS = \$950.00 Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are \$475.00 reduced by 1/2. \$475.00 SUBTOTAL Processing fee of \$130.00 for furnishing English translation later the ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f). TOTAL NATIONAL FEE \$0.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$475.00 TOTAL FEES ENCLOSED Amount to be refunded: charged: A check in the amount of \$609.00 to cover the above fees is enclosed. Please charge my Deposit Account No. to the above fees. in the amount of \$ A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any c. 🛛 overpayment to Deposit Account No. 50-0872. A duplicate copy of this sheet is enclosed. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information d. 🔲 should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Foley & Lardner 402 W. Broadway, Suite 2300 San Diego, California 92101-3542 Telephone: (310) 975-7963

SIGNATURE

NAME MICHAÉL A. WHITTAKER REGISTRATION NUMBER 46,230

Mattan



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Application No. (if known, see

27 CED 1 5)

Unknown

37 CFR 1.5)

International Application No.

PCT/US99/20489

International Filing Date:

10 September 1999

Priority Date Claimed:

11 September 1998

Title of Invention

INHIBITION OF ONCOGENE

TRANSCRIPTION

BY

I IIIE OI IIIVEIIIIOII

SYNTHETIC POLYAMIDES

Applicant(s) for DO/EO/US

California Institute of Technology

Agent÷s Ref:

025098/0603

CERTIFICATE UNDER 37 CFR 1.10

"Express Mail" mailing label number: EL 727050441 US

Date of Deposit: April 10, 2001

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to ATTENTION PCT LEGAL STAFF, BOX PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.

By:

Sandra A'Cos

Attention: PCT Legal Staff

Box PCT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

☐ Transmittal Letter to the United States Designated/Elected Office 9DO/EO/US) Concerning
 A Filing Under 35 USC 371

Petition For Revival of an International Application for Patent Designating the U.S. Abandoned Unintentionally Under 37 CFR 1.137(B)

Check in the amount of \$620.00 for Petition Fee

Check in the amount of \$475.00 for Application Fee

Return Postcard

Please charge any additional fees associated with this transmittal, or credit any overpayment to Deposit Account No. 50-0872. A duplicate of this sheet is enclosed.

FOLEY & LARDNER 402 W. Broadway, Suite 2300 San Diego, CA 92101-8579 1-619-234-6655 Office 1-619-234-3510 Fax

Name: Michael A. Whittaker

Reg. No. 46,230

MAW:snac